FEG
HURA

Financial Enhancement Group’s TuHURA Biosciences HURA Stock Holding History

Financial Enhancement Group’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed -$3K – 320
2021
Q2 		$3K Buy
+1
New +$2.87K ﹤0.01% 234

Other funds holding HURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GSEP
Golden State Equity Partners South Coast Metro, California $1.32B AUM 23.87% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Financial Enhancement Group's HURA Position: Q3 2021 in Review

Financial Enhancement Group sold out of TuHURA Biosciences (HURA) in Q3 2021, closing a stake of 1 share — an estimated $3K sold.

Financial Enhancement Group first reported a position in HURA in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 24 funds tracked by Wall St. Rank hold HURA as of Q3 2021.

  • Financial Enhancement Group reported no remaining TuHURA Biosciences position as of Q3 2021 after selling out during the quarter.
  • Financial Enhancement Group sold 1 TuHURA Biosciences share in Q3 2021, an estimated $3K.
  • Financial Enhancement Group first reported a position in TuHURA Biosciences in Q2 2021 and held it in 1 quarter.
  • Financial Enhancement Group's TuHURA Biosciences position peaked at $3K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q3 2021.

Based on Financial Enhancement Group's 13F filing for Q3 2021, filed 14 Oct 2021.